Darbepoetin Alfa (Aranesp) Market Report 2025

The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.81 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to anemia treatment advancements, erythropoiesis-stimulating agents (ESAs) demand, biopharmaceutical innovation, clinical acceptance, and improved patient outcomes.

The darbepoetin alfa (aranesp) market size is expected to see strong growth in the next few years. It will grow to $7.51 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to healthcare reimbursement policies, increased awareness and education, healthcare infrastructure development, renal care demands, aging population. Major trends in the forecast period include global market penetration, digital health integration, personalized treatment approaches, adoption of biosimilars, and long-acting formulations.

The rising prevalence of chronic diseases is expected to drive the growth of the darbepoetin alfa market in the future. A chronic disease is an illness that lasts three months or longer and can worsen over time. Darbepoetin alfa is used to treat various chronic diseases and to reverse chemotherapy-induced anemia in cancer patients. For instance, in June 2024, the Australian Institute of Health and Welfare, a statutory authority of the Australian Government, reported that chronic conditions were responsible for 171,500 deaths in 2022, accounting for 90% of all deaths, with a rate of 659 per 100,000 population. The age-standardized death rate due to chronic conditions decreased to 448 per 100,000 in 2020 but rose to 459 in 2021 and 490 in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

The rising prevalence of diabetes is expected to propel the growth of the darbepoetin alfa market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. Over time, this condition causes major harm to the heart, blood vessels, eyes, kidneys, nerves, and other organs. Darbepoetin alfa plays a crucial role in diabetes patients by addressing the anemia associated with the condition, promoting red blood cell production, and improving overall quality of life. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed. According to IDF predictions, 783 million adults, or one in eight people, will have diabetes by 2045. This would represent a 46% rise, more than double the projected population growth for the same period (20%). Therefore, the rising prevalence of diabetes is driving the growth of the darbepoetin alfa market.

Product innovation stands out as a significant trend gaining momentum in the darbepoetin alfa market, with major companies strategically adopting new technologies to secure their market positions. GlaxoSmithKline Ltd., a UK-based pharmaceutical and biotechnology company, exemplifies this trend by introducing Jesduvroq (daprodustat) in February 2023. The US Food and Drug Administration (FDA), a US-based government agency, approved Jesduvroq as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the once-daily treatment of anemia induced by chronic kidney disease (CKD) in individuals on dialysis for at least four months.

Major companies in the darbepoetin alfa market are intensifying their focus on introducing novel medications to gain a competitive advantage. A case in point is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to address anemia associated with chronic kidney disease. Akebia Therapeutics, a US-based biotechnology company, obtained approval from Australia's Therapeutic Goods Administration (TGA) for Vafseo in September 2023. This approval extends to 36 countries, including Taiwan, and is based on the positive outcomes from the global Phase 3 clinical program demonstrating the efficacy of vadadustat in treating anemia due to CKD in adults on chronic maintenance dialysis. The commitment to introducing innovative products reflects the dedication of major companies in advancing solutions within the darbepoetin alfa market.

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, acquired Viatris Inc. for an undisclosed amount. This acquisition equips Biocon Biologics with direct commercial capabilities and supporting infrastructure in advanced markets and several emerging markets, bringing it closer to patients, customers, and payors. Viatris Inc. is a U.S.-based provider of darbepoetin alfa.

Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

North America was the largest region in the darbepoetin alfa market in 2024. The regions covered in the darbepoetin alfa (aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the darbepoetin alfa (aranesp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Darbepoetin alfa (Aranesp) is a medication utilized in treating anemia associated with chemotherapy and chronic kidney disease by stimulating the production of red blood cells in the bone marrow.

The primary variations of darbepoetin alfa (Aranesp) include Epogen, Procrit, Aranesp, and other related forms. Epogen is a synthetic protein designed to boost the body's red blood cell production and is specifically employed to address anemia, characterized by a deficiency of red blood cells. These medications are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and find application in treating patients with chronic kidney disease, individuals with cancer, and other relevant medical conditions.

The darbepoetin alfa market research report is one of a series of new reports that provides darbepoetin alfa market statistics, including darbepoetin alfa industry global market size, regional shares, competitors with darbepoetin alfa market share, detailed darbepoetin alfa market segments, market trends, and opportunities, and any further data you may need to thrive in the darbepoetin alfa industry. This darbepoetin alfa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The darbepoetin alfa market consists of sales of Aranesp sure click, Aranesp albumin free, and Aranesp sing eject. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.